OCT 5·SEC EDGARLow
Venker Eric sold $120K of IMVT
Venker Eric (Chief Executive Officer) sold 3,506 shares of Immunovant, Inc. (IMVT) at $34.11 ($0.12M total) on 2026-10-02.
StockNASDAQ · US · USDHealthcare · Biotechnology
$IMVT
Immunovant, Inc.
Price · $IMVTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IMVT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $3.1M 3 txs
Venker Eric2× · $3.0M
10b5-1 share of filings0%
Top stories · $IMVTMore →
OCT 5·SEC EDGAR
Venker Eric sold (to issuer) $2.9M of IMVT
Venker Eric (Chief Executive Officer) sold (to issuer) 85,886 shares of Immunovant, Inc. (IMVT) at $33.65 ($2.89M total) on 2026-10-01.
SEP 27·insidermonkey.com
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Immunovant (IMVT) reported a Phase 2b trial failure for IMVT-1402 in CLE, discontinuing development. Despite missing the primary endpoint, the drug showed positive trends and a favorable safety profile. IMVT-1402 is still being tested in five other autoimmune diseases, with data expected from 2027. The company has $797.8M in cash, and hedge fund interest has increased.
IMVT sentiment & insider activity
Recent IMVT coverage spans insider activity, technology and corporate actions.
In the last 30 days, IMVT insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.1M). The most active reporter was Venker Eric, Chief Executive Officer, with 2 filings.
What's driving IMVT
Insider sale by the chief executive may signal reduced confidence and could weigh on the stock.
The insider sale may signal reduced confidence from the CEO and could weigh on the stock.
The missed primary endpoint is expected to weigh on IMVT shares.
Insider sale by a senior officer may signal limited confidence, modest negative pressure on the stock.
Roivant (ROIV) fell premarket after its subsidiary Immunovant (IMVT) reported a failed trial for IMVT-1402, a treatment for cutaneous lupus erythematosus, based on 12-week data.
AlphAI scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IMVT
Score
Venker Eric sold $120K of IMVT
Venker Eric (Chief Executive Officer) sold 3,506 shares of Immunovant, Inc. (IMVT) at $34.11 ($0.12M total) on 2026-10-02.
1 min readVenker Eric sold (to issuer) $2.9M of IMVT
Venker Eric (Chief Executive Officer) sold (to issuer) 85,886 shares of Immunovant, Inc. (IMVT) at $33.65 ($2.89M total) on 2026-10-01.
1 min read
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Immunovant (IMVT) reported a Phase 2b trial failure for IMVT-1402 in CLE, discontinuing development. Despite missing the primary endpoint, the drug showed positive trends and a favorable safety profile. IMVT-1402 is still being tested in five other autoimmune diseases, with data expected from 2027. The company has $797.8M in cash, and hedge fund interest has increased.
2 min readVan Tuyl Christopher sold $103K of IMVT
Van Tuyl Christopher (Chief Legal Officer) sold 2,846 shares of Immunovant, Inc. (IMVT) at $36.36 ($0.10M total) on 2026-09-23.
1 min readRoivant slips on trial setback for Immunovant (ROIV:NASDAQ)
Roivant (ROIV) fell premarket after its subsidiary Immunovant (IMVT) reported a failed trial for IMVT-1402, a treatment for cutaneous lupus erythematosus, based on 12-week data.
1 min readImmunovant stock falls after lupus drug trial misses goal
Immunovant (IMVT) shares dropped 6% after its lupus drug trial failed to meet the primary endpoint. The study did not show statistical significance in improving CLE symptoms. The company plans to halt development of IMVT-1402 for this indication but will continue trials for other autoimmune diseases. According to Immunovant, the drug showed a favorable safety profile.
2 min readImmunovant, Inc. (IMVT): Submission of Matters to a Vote of Security Holders
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 2, 2026, Immunovant, Inc. ( “ Immunovant ” ) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ” ). There were 198,373,370 shares of common stock and Series A preferred stock represented
3 min readGloria Melanie sold $135K of IMVT
Gloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
1 min readWhy Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype
Immunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
5 min readImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory dem
4 min read